Skip to main content

PneumoniaCheck, a novel aerosol collection device, permits capture of airborne Mycobacterium tuberculosis and characterisation of the cough aeromicrobiome in people with tuberculosis

Abstract

Background

Tuberculosis (TB), a major cause of disease and antimicrobial resistance, is spread via aerosols. Aerosols have diagnostic potential and airborne-microbes other than Mycobacterium tuberculosis complex (MTBC) may influence transmission. We evaluated whether PneumoniaCheck (PMC), a commercial aerosol collection device, captures MTBC and the aeromicrobiome of people with TB.

Methods

PMC was done in sputum culture-positive people (≥ 30 forced coughs each, n = 16) pre-treatment and PMC air reservoir (bag, corresponding to upper airways) and filter (lower airways) washes underwent Xpert MTB/RIF Ultra (Ultra) and 16S rRNA gene sequencing (sequencing also done on sputum). In a subset (n = 6), PMC microbiota (bag, filter) was compared to oral washes and bronchoalveolar lavage fluid (BALF).

Findings

54% (7/13) bags and 46% (6/14) filters were Ultra-positive. Sequencing read counts and microbial diversity did not differ across bags, filters, and sputum. However, microbial composition in bags (Sphingobium-, Corynebacterium-, Novosphingobium-enriched) and filters (Mycobacterium-, Sphingobium-, Corynebacterium-enriched) each differed vs. sputum. Furthermore, sequencing only detected Mycobacterium in bags and filters but not sputum. In the subset, bag and filter microbial diversity did not differ vs. oral washes or BALF but microbial composition differed. Bags vs. BALF were Sphingobium-enriched and Mycobacterium-, Streptococcus-, and Anaerosinus-depleted (Anaerosinus also depleted in filters vs. BALF). Compared to BALF, none of the aerosol-enriched taxa were enriched in oral washes or sputum.

Interpretation

PMC captures aerosols with Ultra-detectable MTBC and MTBC is more detectable in aerosols than sputum by sequencing. The aeromicrobiome is distinct from sputum, oral washes and BALF and contains differentially-enriched lower respiratory tract microbes.

Background

Tuberculosis (TB) is a serious global health concern, with an estimated 10.6 million cases and 1.3 million fatalities in 2022 [1]. Not only does TB remain challenging to diagnose with an urgent need for non-sputum based tests but the characteristics of cough aerosols from people with TB, which are a determinant of transmission success, are poorly understood [2, 3].

Breath-based detection of Mycobacterium tuberculosis complex (MTBC) DNA is a promising non-sputum method for diagnosing TB, with face masks and blow tubes under evaluation [4,5,6]. PneumoniaCheck (PMC), a cough aerosol collection device, has been evaluated in people with cystic fibrosis (CF) [7] and viral pneumonia [8]. In the first study, CF-related bacteria were in the aerosols of 65% of people sputum-positive for these bacteria (and aerosol did not contain lung commensals found in sputum). In the second study, when pathogen readouts from PMC and bronchoalveolar lavage fluid (BALF) were compared, 66% of aerosols were PCR-positive. PMC, is however, unevaluated in TB where, in addition to detecting MTBC in exhaled aerosols, it could be used to characterise the aeromicrobiome, which may influence contacts’ immune responses.

The microbiota is a topic of increasing interest in TB, where sputum is widely studied. However, the sputum microbiota more closely resembles the upper respiratory tract (URT) than the lower respiratory tract (LRT) [9, 10], which is the primary site-of-disease in TB. Sampling the LRT is difficult because it requires bronchoscopy [11], which is invasive, ethically complex for research purposes only, and expensive, often rendering it unfeasible in large cohorts where TB is prevalent [12]. Aerosols, which are more accessible, could be a useful proxy for studying the LRT, as aerosols partly originate from the LRT [13].

PMC comprises a 250mL air reservoir (bag) attached to a mouthpiece with a filter. PMC is designed to separate aerosols from the URT and LRT into the bag and filter, respectively [14]. This separation occurs after a person coughs into the PMC, at which point air from the anatomical URT dead space (~ 150mL) [15] flows first into the bag. Air after the 150mL is likely from the LRT and then, due to backpressure from the inelastic bag, directed towards the filter [7].

It is thus possible that, in addition to PMC-captured aerosols being useful for TB diagnosis, such aerosols may serve as an alternative to BALF for LRT microbiota characterization and more accurately represent the vehicle of TB transmission, including compared to oral washes and sputum. We therefore evaluated MTBC detection by Xpert MTB/RIF Ultra (Ultra) and the bag and filter microbiota. We compared microbiota in the bag and filter to URT and LRT clinical samples.

Methods

Ethics

The study was conducted in accordance with the Declaration of Helsinki. Stellenbosch University Health Research Ethics Committee (SU-HREC) approved the study (N14/10/136, N16/05/070). People provided a written informed consent.

Recruitment and data collection

This study involved people (n = 16; ≥18 years) enrolled at primary healthcare facilities in Cape Town. People were sputum MTBC culture-positive and not on treatment. Clinical and demographic data were collected.

Sample collection

People first gave aerosols collected using PMC and sputum was then induced. For aerosols, people were asked to take deep breaths to stimulate a cough. While sealing lips around the PMC mouthpiece ridge, with teeth rested on the device notches, people were asked to produce ≥ 30 deep coughs (Fig. 1). Bags were deflated by hand squeezing after each cough. People who had adverse effects like dizziness could rest between coughs and, if they produce sputum during coughing, were given a jar in which to expectorate. DNA sampling background controls (BKG) were collected to identify potentially contaminating taxa and included an unused PMC handled in the same manner as those used by people. Sputum was induced with 5% saline for 10 min. Oral washes (representing URT) and BALF (representing LRT) were also collected in a subset (n = 6) of the 16 people (Supplementary Methods). This subset had been enrolled into a separate study examining site-of-disease immunological signatures (NCT03350048).

Fig. 1
figure 1

How to use pneumonia check (PMC): People seal their lips around the mouthpiece ridge and cough into the PMC. As they exhale, air from the anatomical dead space moves into the inelastic air reservoir (bag), while additional air, primarily from the lower respiratory tract (LRT) is directed towards the filter

Respiratory fluids processing

Oral washes and sputum were decontaminated using N-acetyl-L-cysteine (NALC), pelleted (3,217xg), resuspended in 2mL PB (pH 6.8; BD, South Africa) and stored at -80 °C [16]. 1mL raw BALF aliquots were stored at -80 °C for microbiota analysis. MTBC in sputum was detected using the Xpert MTB/RIF (Xpert) and Mycobacteria Growth Indicator Tube (MGIT) 960 liquid culture according to the manufacturers’ methods.

Recovery and processing of aerosols

Aerosols were separately recovered from the PMC bag and filter. After removal under sterile conditions, bags were rinsed and incubated for 15 min in 10mL stripping buffer (1% Triton X-100 in 10mM Tris-HCl, pH 8.0) whereas the filter was submerged in 10mL stripping buffer, vortexed vigorously for one minute, and incubated for 30 min. Bag and filter washes were pelleted (3,217xg) and resuspended in 1.5mL PB. Aliquots of 0.7mL each for MTBC testing using Ultra (version 2, according to the manufacturers’ methods) and microbiota analysis were stored at -80 °C.

16S rRNA gene sequencing and analysis

Microbial DNA was extracted using the QIAamp DNA Mini kit (QIAGEN, Hilden, Germany). 16S rRNA gene sequencing (V4 region, 150 bp read length, paired end) was done on Illumina MiSeq platform [16, 17]. Sequences were analysed using QIIME 2-2020.2 [18]. We included samples with a minimum read count of 1000. Reads were clustered into amplicon sequence variants (ASVs) using DADA2 (version 1.1.6) [19] and taxonomy assigned at 99% similarity against GreenGenes [20]. α-Diversity (Shannon index) and β-diversity (Bray-Curtis dissimilarity index) were calculated using vegan [21]. Non-parametric methods (Mann-Whitney, Wilcoxon, Kruskal-Wallis, or Friedman tests for unpaired and paired comparisons) were used, whilst permutational multivariate analysis of variance (PERMANOVA) was used for β-diversity. DESeq2 [22] was used for differential abundance analyses with Benjamini-Hochberg multiple comparison adjustment. Potentially contaminating background taxa were identified using decontam (version 1.14.0) [23]. Taxa identified as possible contaminants were not removed from downstream analysis but greyed-out in volcano plots only if identified as differential.

Results

Study population

We included 16 people of median (IQR) age of 35 (25, 46) years. 31% (5/16) were HIV-positive, 75% (12/16) tobacco smokers, and 94% (15/16) of mixed ancestry (Table 1). Median (IQR) days to culture-positivity (TTP) was 5 (5, 7).

Table 1 Demographic and clinical characteristics. Data are median (IQR) or n (%)

Ultra on aerosols

Ultra sensitivity on bags and filters washes was 54% (7/13) and 43% (6/14, p = 0.568), respectively (Table 2). No sputum culture TTP differences occurred when compared based on the bag or filter Ultra results nor were there differences in Ultra-generated IS1081-IS6110 CTs. Ultra-generated sample processing control (SPC) cycle threshold (CT) values, a measure of PCR inhibition [24], were similar when across bag and filter washes and when compared across people who had Ultra-positive vs. -negative bags or Ultra-positive vs. -negative filters.

Table 2 Summary of ultra-based MTBC detection in aerosols, showing Ultra results when applied to the bag and filter of PMC. There was no difference in sputum bacillary load (TTP) and PCR-inhibition across all comparisons. Data are % (n/N) or median (IQR) or mean (± SD)

A distinct aeromicrobiome is detectable over and above background aerosol

The number of reads did not differ in sputum, bags, and filters in per person comparisons (nor in people who also had oral washes and BALFs sequenced) (Figure S1a-b). Given aerosols have low microbial biomass, we compared the microbiota in aerosol-exposed bags and filters to BKG to check for contamination. α-Diversity was similar between BKG and aerosols (p = 0.430, Figure S2a), but β-diversity differed (PERMANOVA; p = 0.001, Figure S2b), with some bag and filter samples grouping with BKG. Potential bag- and filter-contaminating taxa included Pseudomonas-, Anaerosinus-, Alistipes and-Kocuria (full list in Table S1, Figure S3), however, none of these were differential in other analyses.

Compared to sputum, the aeromicrobiome differs and Mycobacterium is more detectable in the filter

Aerosols vs. sputum

α-Diversity (p = 0.223) was similar yet β-diversity (PERMANOVA; p = 0.001) differed (Fig. 2a-b). Aerosols were compositionally distant from sputum (Figure S4a-b). Bags were Sphingobium-, Corynebacterium- and Novosphingobium-enriched, and Anaerosinus-, Streptococcus- and Neisseria-depleted vs. sputum (Fig. 2c). Filters were Mycobacterium-, Sphingobium- and Corynebacterium-enriched, and Anaerosinus-, Streptococcus- and Neisseria-depleted vs. sputum (Fig. 2d).

Fig. 2
figure 2

Aerosol microbiota is compositionally distinct from sputum: (a) paired α-diversity (Shannon index) using Friedman test for bag, filter, and sputum. (b) β-diversity (Bray-Curtis dissimilarity index), shows distinct clustering of sputum and aerosols. Volcano plots showing differentially abundant taxa in (c) bag vs. sputum, and (d) filter vs. sputum. Taxa that are considered discriminatory appear above threshold (marked by the red dotted line, FDR = 0.2). The size of the dots corresponds to the relative abundance of the taxa

Bags vs. filters

α-Diversity and β-diversity (p = 0.223 and PERMANOVA; p = 0.868) were similar between filters and bags (Fig. 2a-b) and differential abundance analyses showed no differential taxa (data not shown).

The aeromicrobiome is not comparable to oral wash nor BALF

α-Diversity was similar in aerosols and across respiratory fluids (p = 0.267, Fig. 3a).

Fig. 3
figure 3

Aerosol microbiota neither similar to oral wash nor bronchoalveolar lavage fluid (BALF): (a) Paired α-diversity (Shannon index) using Friedmann test for bag, filter, sputum oral washes, and BALF (b) β-diversity (Bray-Curtis dissimilarity index) showing distinct clustering patterns for aerosols, sputum, oral washes and BALF. Volcano plots showing differentially abundant taxa in (c) bags vs. oral wash, (d) filters vs. oral wash, (e) bags vs. BALF, and (f) filters vs. BALF. Taxa that are considered discriminatory appear above threshold (marked by the red dotted line, FDR = 0.2). The size of the dots corresponds to the relative abundance of the taxa. Taxa identified as potential contaminants are depicted in grey in the volcano plots

Aerosols vs. oral wash

Oral wash β-diversity differed from bags and filters (PERMANOVA p = 0.005 and 0.002, respectively; Fig. 3b). Aerosols were compositionally different to oral washes (Figure S4c) with bags Sphingobium- and Corynebacterium-enriched and Anaerosinus-, Streptococcus- and Prevotella-depleted (Fig. 3c) and filters Mycobacterium-, Pseudomonas- and Sphingobium-enriched and Anaerosinus-, Streptococcus- and Campylobacter-depleted (Fig. 3d).

Aerosols vs. BALF

BALF β-diversity differed from bags and filters (PERMANOVA; p = 0.005 and 0.004 respectively, Fig. 3b). Aerosols were compositionally different to BALF (Figure S4d) with bags Sphingobium-enriched and Anaerosinus-, Streptococcus- and Mycobacterium-depleted and filters Anaerosinus-depleted (Fig. 3e-f).

Differential abundance across sputum, oral wash, and bronchoalveolar lavage fluid

In BALF vs. sputum, Mycobacterium- was enriched and Campylobacter-, Sebaldella-, and Prevotella-depleted. In BALF vs. oral wash, Mycobacterium- was enriched and Prevotella-, Campylobacter-, and Treponema-depleted (Figure S5a-b).

Discussion

We evaluated detection of MTBC and aeromicrobiome captured by PMC in people with TB. Our data shows (1) MTBC is detectable by Ultra in aerosols in about 57% of TB-positive people with comparable sensitivity in bags and filters, (2) bag and filter microbiota are compositionally similar, but differ to a similar extent vs. sputum, oral wash and BALF; and (3) the filter captures Mycobacterium more readily sequenced than in sputum and Mycobacterium itself is comparatively overrepresented in the aeromicrobiome vs. sputum. These findings show proof-of-concept for a novel sampling method for evaluating the aeromicrobiome, which we show is phylogenetically different from the microbiota in other respiratory fluids of people with TB.

The PMC bags and filters retained aerosols containing MTBC detectable using the WHO-recommended molecular test Ultra. This is consistent with studies that show PMC to capture LRT microbes in other diseases [7, 8]. We did not detect differences in mycobacterial load nor PCR inhibition when comparing bags and filters, suggesting both PMC components may be useful, however, further optimization of aerosol collection procedures (e.g., number of coughs sufficient) and processing (to optimise release of captured material) require future investigation.

Diversity and composition metrics (α- and β-diversity) were similar between bags and filters; suggest a potential lack of separation of PMC-collected aerosols to URT and LRT. As the primary purpose of the bag is to collect URT aerosols (~ 150mL in typical adults) but the volumetric capacity of the bag is 250mL, it is conceivable the bag retains aerosols originating from LRT in addition to URT, resulting in a mixture of LRT and URT microbiota.

The aeromicrobiome differed from sputum, oral wash, BALF microbiota, with aerosol depleted of anaerobic taxa such as Prevotella and Streptococcus, previously described as enriched in TB patients’ sputa and oral washes [16] and highlighting that abundance in respiratory fluids does not necessarily translate into abundance in aerosol (previously described only for MTBC) [25]. Mycobacterium was more detectable by sequencing in filter-captured aerosol than sputum, where sequencing this genus can be challenging even in people with severe pulmonary disease (TB and non-TB mycobacterial disease) [10, 16]. This agrees with a prior study that did sequencing on mask-captured aerosol from people with TB [26]. Collectively, these findings suggests that, amongst the respiratory flora in people with TB, Mycobacterium is especially adept at aerosolization, permitting it to be the dominant taxon in aerosol. Besides the enrichment of Mycobacterium in aerosols vs. sputum, Sphingobium and Corynebacterium were enriched, however, their role in TB airborne survival and transmission requires future evaluation.

Our study has strengths and limitations. Although it is the largest to date on this topic in people with TB and included invasive and expensive forms of sampling (bronchoscopy), different findings might result from larger sample sizes, especially for the diagnostic accuracy analyses. As such as our findings should be regarded as explorative and hypothesis generating. They therefore help justify larger expensive studies which, for reasons of capacity, were not possible in the current work. Potential for a larger study was also constrained due to a dependency on parent studies to refer participants (these studies have now stopped). While this enhanced feasibility and resulted in important comparisons being possible (for example, with site-of-disease fluid), it resulted in not all people receiving all procedures. While in this study no cultures were performed on aerosols because the samples were only enough for Ultra and sequencing, we recommend future studies to explore whether these aerosols can be cultured. We also only evaluated people with TB; aerosol from people without TB may have different differential taxa. Future studies could also compare aerosols in relation to additional samples from the aerodigestive tract like bronchial aspirations.

In summary, PMC captures aerosols which can be used to detect MTBC using WHO-approved molecular tests and sequencing. The taxonomic composition of aerosol differs to that in other respiratory fluids. This work lays a foundation for research on the aeromicrobiome in TB.

Data availability

Data is available on reasonable request. Study protocol and datasets generated in this study maybe requested from the corresponding author.

References

  1. World Health Organization. Global tuberculosis report 2023.

  2. Turner RD, Bothamley GH. Cough and the transmission of tuberculosis. J Infect Dis. 2015;211(9):1367–72.

    Article  PubMed  Google Scholar 

  3. Jones-López EC, Namugga O, Mumbowa F, et al. Cough aerosols of Mycobacterium tuberculosis predict new infection. A household contact study. Am J Respir Crit Care Med. 2013;187(9):1007–15.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Abdulgader SM, Okunola AO, Ndlangalavu G, et al. Diagnosing tuberculosis: what do New Technologies allow us to (not). Do? Respiration. 2022;101(9):797–813.

    Article  PubMed  Google Scholar 

  5. Williams CM, Abdulwhhab M, Birring SS, et al. Exhaled Mycobacterium tuberculosis output and detection of subclinical disease by face-mask sampling: prospective observational studies. Lancet Infect Dis. 2020;20(5):607–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Nathavitharana RR, Garcia-Basteiro AL, Ruhwald M, Cobelens F, Theron G. Reimagining the status quo: How close are we to rapid sputum-free tuberculosis diagnostics for all? EBioMedicine 2022.

  7. Ku DN, Ku SK, Helfman B et al. Ability of device to collect bacteria from cough aerosols generated by adults with cystic fibrosis. F100 Research 2016; 5(1920).

  8. Patrucco F, Gavelli F, Ravanini P, et al. Use of an innovative and non-invasive device for virologic sampling of cough aerosols in patients with community and hospital acquired pneumonia: a pilot study. J Breath Res. 2019;13(2):021001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Durack J, Huang YJ, Nariya S, et al. Bacterial biogeography of adult airways in atopic asthma. Microbiome. 2018;6(1):104.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Sulaiman I, Wu BG, Li Y et al. Evaluation of the airway microbiome in nontuberculous mycobacteria disease. Eur Respir J 2018; 52(4).

  11. Shaw JA, Meiring M, Allies D, et al. Optimising the yield from bronchoalveolar lavage on human participants in infectious disease immunology research. Sci Rep. 2023;13(1):8859.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Sulaiman I, Schuster S, Segal LN. Perspectives in lung microbiome research. Curr Opin Microbiol. 2020;56:24–9.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Polverino M, Polverino F, Fasolino M, Andò F, Alfieri A, De Blasio F. Anatomy and neuro-pathophysiology of the cough reflex arc. J Multidisciplinary Respiratory Med. 2012;7(1):1–5.

    Google Scholar 

  14. Scholz TL, Midha PA, Anderson LJ, Ku DN. PneumoniaCheck: a device for sampling lower airway aerosols. J Med Devices 2010; 4(4).

  15. Hart M, Orzalesi M, Cook C. Relation between anatomic respiratory dead space and body size and lung volume. J Appl Physiol. 1963;18(3):519–22.

    Article  CAS  PubMed  Google Scholar 

  16. Naidoo CC, Nyawo GR, Sulaiman I, et al. Anaerobe-enriched gut microbiota predicts pro-inflammatory responses in pulmonary tuberculosis. EBioMedicine. 2021;67:103374.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Segal LN, Clemente JC, Li Y, et al. Anaerobic bacterial fermentation products increase tuberculosis risk in antiretroviral-drug-treated HIV patients. Cell Host Microbe. 2017;21(4):530–7. e4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol. 2019;37(8):852–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13(7):581–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. McDonald D, Price MN, Goodrich J, et al. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J. 2012;6(3):610–8.

    Article  CAS  PubMed  Google Scholar 

  21. Dixon P. Vegan, a package of R functions for community ecology. J Veg Sci. 2003;14(6):927–30.

    Article  Google Scholar 

  22. Love MI, Huber W, Anders S. Moderated estimation of Fold change and dispersion for RNA-seq data with DESeq2. J Genome Biology. 2014;15(12):550.

    Article  Google Scholar 

  23. Davis NM, Proctor DM, Holmes SP, Relman DA, Callahan BJJM. Simple statistical identification and removal of contaminant sequences in marker-gene and metagenomics data. Microbiome. 2018;6(1):1–14.

    Article  Google Scholar 

  24. Blakemore R, Nabeta P, Davidow AL, et al. A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay. Am J Respir Crit Care Med. 2011;184(9):1076–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Theron G, Limberis J, Venter R, et al. Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosis. Nat Med. 2020;26(9):1435–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Nardell EA, Williams CM, Bell AJ, et al. TB airborne transmission: first gene expression signatures of captured, uncultured M. Tuberculosis from human source aerosol. D107 tuberculosis infection and disease. Epidemiology and Diagnosis: American Thoracic Society; 2016. pp. A7934–A.

    Google Scholar 

Download references

Acknowledgements

The authors thank study participants and CLIME clinical research staff especially Sr Ruth Wilson. Computations were performed using facilities provided by the University of Cape Town’s ICTS High Performance Computing team: hpc.uct.ac.za.

Funding

This work and authors are supported by the Deutscher Akademischer Austauschdienst (ST32-PKZ-91770486), European & Developing Countries Clinical Trials Partnership (EDCTP; project numbers SF1041, TMA2017CDF-1914-MOSAIC and TMA2019CDF-2738- ESKAPE-TB), National Research Foundation (NRF), the South African Medical Research Council (SAMRC), Harry Crossley Foundation, Stellenbosch University Faculty of Health Sciences, and National Institutes of Health under award numbers (R01AI136894; U01AI152087; U54EB027049; D43TW010350; K43TW012302).

Author information

Authors and Affiliations

Authors

Contributions

TC, GN, SM, CN and GT conceived and designed the study and wrote the first draft. TC, GN, CN, SM, DK, JC, RW, STM, LNS, and GT were all involved in data analysis and interpretation. All authors contributed to the revising the manuscript.

Corresponding author

Correspondence to Grant Theron.

Ethics declarations

Ethical approval

Stellenbosch University Health Research Ethics Committee (SU-HREC) approved the study (N14/10/136, N16/05/070).

Consent to participate

People provided a written informed consent to participate in the study.

Consent to publish

Not applicable.

Completing interests

DK is a co-inventor of the PneumoniaCheck patent, which has been licensed to MD Innovate, Inc. by the US Centres for Disease Control and Prevention and Georgia Tech Research Corporation. GT received in-kind donations of PMC devices from MD Innovate, which played no role in the study design or interpretation of results.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Supplementary Material 2

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chiyaka, T.L., Nyawo, G.R., Naidoo, C.C. et al. PneumoniaCheck, a novel aerosol collection device, permits capture of airborne Mycobacterium tuberculosis and characterisation of the cough aeromicrobiome in people with tuberculosis. Ann Clin Microbiol Antimicrob 23, 74 (2024). https://doi.org/10.1186/s12941-024-00735-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12941-024-00735-x

Keywords